Anavex enters collaborative agreement with Ariana Pharma

Anavex Life Sciences Corp. has entered into a collaborative agreement with Ariana Pharma to allow Anavex to use Ariana's proprietary Knowledge, Extraction, Management (KEM) stratification technology to expedite the clinical development timelines of its ANAVEX 2-73 Phase 2/3 trial.

"We are very impressed with the rational and efficient clinical trial path Anavex has embarked upon by adopting population pharmacokinetics (PK) and adaptive trial design in its current ANAVEX 2-73 Phase 2a study in Alzheimer’s disease," Ariana Pharma CEO Mohammad Afshar said. "Ariana has the expertise to fully support Anavex’s precision medicine approach to develop more effective treatments for devastating diseases including Alzheimer’s, Parkinson’s and Rett syndrome."

KEM is an all-inclusive data analysis system that allows for the utilization of complex datasets.

"The ongoing Phase 2a Alzheimer’s clinical trial was specifically designed to learn as much as possible about ANAVEX 2-73 in order to optimize trial parameters for future pivotal trials and potentially reduce the risk of failure in a later, larger Phase 2/3 study and in a planned Parkinson’s Phase 2 study," Anavex President and CEO Christopher Missling said. "We believe that the collaboration with Ariana Pharma will potentially accelerate the development process."